Sharps Technology Reports $17.7M in Q3 Revenue Gains From Digital Assets and Staking

Author: Benzinga Newsdesk | November 17, 2025 07:55am

Sharps Technology, Inc. ("STSS" or the "Company"), a U.S.-based medical device sales and distribution platform that has adopted a Solana-based treasury strategy, today announced financial results for the third quarter ended September 30, 2025, and provided updates on the execution of its capital markets and digital asset initiatives.

"The third quarter was transformative for Sharps Technology," said Paul K. Danner, Executive Chairman. "Our adoption of a Solana-based treasury strategy, combined with a successful $411 million PIPE financing, has created the strongest balance sheet in the Company's history. With more than two million SOL in our treasury, growing staking rewards, and a more efficient operating model, Sharps is now better positioned to pursue more viable business strategies and deliver long-term value for shareholders."

Key Highlights from Q3 2025:

• The Company raised gross proceeds of $411 million through a PIPE funded with $267 million in cash and stablecoins and $144 million in SOL.
• As of October 31, 2025, STSS holds over 2.0 million SOL in its treasury. 
• In the third quarter, STSS generated approximately $17.7 million of combined staking revenue and digital-asset fair-value gains. The Company's cash and stablecoin liquidity stands at approximately $25.2 million as of September 30, 2025.
• STSS warrantholders exercised 315,805 Series A warrants for net proceeds of $1.9 million and 388,462 pre-funded warrants were exercised for nominal cash consideration.
• The Company entered into a settlement agreement with Barry Berler, Plastomold Industries Ltd., Plasto Design entities, and Plasto Technology Group LLC providing for full mutual releases and closing all claims associated with prior litigation.
• Sharps Technology completed its planned exit from legacy syringe manufacturing, significantly streamlining operations and reducing ongoing costs. With this transition, the Company is now fully focused on two strategic priorities: (1) sale and distribution of medical device products, and (2) maximizing the value of its SOL-based digital asset treasury. Together, these initiatives position the Company to drive higher margins, strengthen its financial profile, and enhance long-term shareholder value.
  
  
  
   

Going forward, Sharps enters the fourth quarter of 2025 with a significantly strengthened financial position, meaningful digital asset income streams, and a simplified operating footprint. Management remains focused on maintaining its medical device distribution business, optimizing yields across its Solana ecosystem holdings, and leveraging capital markets access to support long-term growth.

Posted In: STSS